Search

Search Constraints

You searched for: Author/Creator Brunetta, Jason

Search Results

1. 1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results. (15th December 2022)

2. 985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial. (31st December 2020)

3. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen. (June 2019)

5. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment. (1st May 2016)

6. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults. (1st November 2016)

7. Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate– to tenofovir alafenamide–containing ART among individuals with HIV in Canada: A retrospective study. (August 2021)

8. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 7 (July 2021)

9. P087 Providers' views on barriers and facilitators of bacterial STI testing among gbMSM living with or at risk for HIV. (14th July 2019)